10/54/20

=> dis his

(FILE 'HOME' ENTERED AT 12:05:11 ON 26 SEP 2007)

FILE 'CAPLUS' ENTERED AT 12:05:38 ON 26 SEP 2007 L1 1 S JP06145539/PN

FILE 'REGISTRY' ENTERED AT 13:43:03 ON 26 SEP 2007

L2 STR L3 7 S L2 L4 STR L2 L5 0 S L4 L6 6 S L4 FUL


FILE 'CAPLUS' ENTERED AT 14:01:26 ON 26 SEP 2007

. L7 1 S L6

=> d 12

L2 HAS NO ANSWERS

L2 STR



NODE ATTRIBUTES:

AT 3 HCOUNT IS E1 ATHCOUNT IS E1 HCOUNT IS E1 AT6 7 HCOUNT IS E1 ATHCOUNT IS E2 AT10 HCOUNT IS E2 ATDEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED


GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE

=> d 14 L4 HAS NO ANSWERS

L4 STR



REP G1 = (0-6) A NODE ATTRIBUTES: HCOUNT IS E1 HCOUNT IS E1 HCOUNT IS E1 ATATAT IS E1 7 HCOUNT AT HCOUNT IS E2 AT10 AT 12 HCOUNT IS E2 DEFAULT MLEVEL IS ATOM DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES: RING(S) ARE ISOLATED OR EMBEDDED NUMBER OF NODES IS 17

STEREO ATTRIBUTES: NONE

=>

=> s 16

L7 . 1 L6

=> d cbib abs

ANSWER 1 OF 1 CAPLUS COPYRIGHT 2007 ACS on STN L7Document No. 139:133834 Preparation of eponemycin and epoxomicin 2003:570973 analogs for pharmaceutical use. Agoulnik, Sergei; Akasaka, Kozo; Fang, Frank; Harmange, Jean-Christophe; Hawkins, Lynn; Jiang, Yimin; Johannes, Charles; Li, Xiang-Yi; Mcguinness, Pamela; Murphy, Erin; Schiller, Shawn; Vermeulen, Mary; Wu, Jiayi (Eisai Co., Ltd., Japan). PCT Int. Appl. WO 2003059898 A2 20030724, 131 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). CODEN: PIXXD2. APPLICATION: WO 2003-US390 20030108. PRIORITY: US 2002-346711P 20020108; US 2002-373011P 20020416.

GI

The invention provides peptides I [A, J, D, E, and G are absent, CRA, AB CRARB, CO, O, S, NRA, or N, where RA and RB are H, a protecting group, or a (hetero)aliphatic, (hetero)alicyclic, or (hetero)aryl group; A and J, J and D, D and E, and D and G are linked by a single or double bond, as valency permits; w, x, y, and z are independently 0-6, but the sum of x, y and z is 0-6; R1-R4 are H, halo, -CN, -ORC, -SRC, -NRcRD, CORC, or a (hetero)aliphatic, (hetero)alicyclic, or (hetero)aryl group; RC, RD are as defined for RA/RB; or NRCRD is a heterocyclic or heteroaryl group; any two adjacent R1-R4 can form a (hetero)alicyclic or (hetero)aryl group; R5, R6 are (hetero)aliphatic, (hetero)alicyclic, or (hetero)aryl; Q is an O-containing heteroaliph. or heteroalicyclic moiety] for use in the treatment of cancer and/or inflammatory disorders, and more generally as proteasome inhibitors. Thus, peptide II (ER-804191) was prepared by a multistep procedure involving coupling of serine and leucine derivs. A graphical representation depicts comparative human breast carcinoma cell growth inhibition of paclitaxel and exemplary compds. of the invention.